Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.

"Declarations Ethics approval and consent to participateThis study was approved by the institutional review board of Seoul National University Hospital. The need for informed consent was waived on account of the retrospective nature of the study. Consent for publicationNot applicable. Competing interestsHBL and WH are co-founders and members of the DCGen Co., Ltd board of directors. HBL received research funding from Devicor Medical Product, Inc., and consulting fees from Need Inc., outside the current work. Other authors declare that they have no competing interests. Competing interests HBL and WH are co-founders and members of the DCGen Co., Ltd board of directors. HBL received research funding from Devicor Medical Product, Inc., and consulting fees from Need Inc., outside the current work. Other authors declare that they have no competing interests."

"Funding HGM was supported by a KHIDI R&D project (HI19C0481, HC21C0031, HI22C0497), funded by the Ministry of Health & Welfare, Republic of Korea and National Research Foundation of Korea (NRF) grant (NRF-2019R1A2C2005277) funded by the Ministry of Science and ICT, Republic of Korea (MSIT)."